Supported byOwner's Engineer
Clarion Energy banner

Valeant from Canada takes over PharmaSwiss for €350 million

Supported byspot_img

Valeant Pharmaceuticals International from Canada and PharmaSwiss S.A. from Switzerland have signed a preliminary agreement on the acquisition of PharmaSwiss S.A.

PharmaSwiss S.A. produces generic drugs, which it sells under its name, and non-prescription drugs. Valeant is to pay €350 million for the acquisition.

Supported by

After the sales contract is concluded, PharmaSwiss will have about €38 million in cash and no debt.


Supported by

Supported by


Supported byClarion Energy
Serbia Energy News
error: Content is protected !!